GlaxoSmithKline’s new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc’s consumer products business, but would not overpay for the asset.
Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire.
“At this stage it would be weird if we didn’t look at it,” GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco.
But she said it is only a look and very early, adding, “we don’t need it and we won’t overpay for it.”
Despite her consumer products background, Walmsley repeatedly said that the company’s pharmaceuticals business and pharma research and development is GSK’s top priority.
However, Walmsley said GSK has a good track record of integrating large acquisitions and that it’s consumer business does have room to grow.
Pfizer’s consumer portfolio includes well-known brands such as Advil, Chapstick lip balm and Centrum vitamins.
Walmsley said there are a very small number of assets that would be completely complementary to GSK’s existing consumer business, “and this may be one of them.”
“If we did it, it is cash generating,” she said.
By Bill Berkrot
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.